Abstract Number: 0561 • ACR Convergence 2025
Patient Characteristics and Treatment Patterns of Traditional and Advanced Therapies Prior to First Secukinumab Intravenous (IV) Administration in Patients with Spondyloarthritis (SpA) in US Real-World Clinical Settings
Background/Purpose: Since most approved biologics are administered subcutaneously, there is a need for alternate routes of delivery to treat patients with SpA. Secukinumab is an…Abstract Number: 0490 • ACR Convergence 2025
Infection Risks Associated with Monotherapy and Combination Therapies Using Biological or Targeted – DMARD in RA: A Systematic Review and Network Meta-analysis
Background/Purpose: This study aimed to evaluate the infection risks in patients with rheumatoid arthritis (RA) treated with biological or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs),…Abstract Number: 0202 • ACR Convergence 2025
Saudi Society for Rheumatology Consensus Recommendation on Vaccination Strategies in Adults Saudi with Autoimmune Rheumatic Disorders
Background/Purpose: Patients with autoimmune inflammatory rheumatic diseases (AIIRD) are at increased risk of infections due to both immune system dysfunction and the use of immunosuppressive…Abstract Number: 2682 • ACR Convergence 2025
Methotrexate use and higher age impair humoral response against the recombinant herpes zoster vaccine (RZV) in Rheumatoid Arthritis: a prospective, randomized, placebo-controlled trial
Background/Purpose: The recombinant vaccine against herpes zoster (HZ) (RZV) is recommended by ACR and EULAR for immunocompromised individuals. Short-term observational data from RA cohorts aged…Abstract Number: 2270 • ACR Convergence 2025
ACKR1 and Leukopenia in Patients with Rheumatoid Arthritis Treated with Disease Modifying Antirheumatic Drugs
Background/Purpose: Disease-modifying antirheumatic drugs (DMARDs) such as methotrexate, sulfasalazine, and leflunomide arecommonly prescribed for RA treatment but carry the risk of leukopenia. The ACKR1 promoter…Abstract Number: 1598 • ACR Convergence 2025
Use of JAK Inhibitors in Medium- and Small-Sized Vasculitides: a Retrospective Multicenter Study
Background/Purpose: Medium- and small-vessel vasculitides (MVV and SVV) are a heterogeneous group of inflammatory diseases affecting the vascular wall. Current treatment strategies are based on…Abstract Number: 1348 • ACR Convergence 2025
Real World Evaluation on the Effectiveness of Baricitinib or Other Treatments in Patients With Rheumatoid Arthritis: Data from the European and Non-European Cohorts of the RA-BE-REAL Study
Background/Purpose: Here, we provide descriptive baseline characteristics and effectiveness outcomes of Baricitinib (BARI) and other ts/bDMARDs at 24-month (24M) in both European (EU) and non-European…Abstract Number: 1089 • ACR Convergence 2025
Comparing the immunosuppressant burden in immune checkpoint inhibitor mediated inflammatory arthritis versus polymyalgia rheumatica: results from a prospective multicenter registry
Background/Purpose: Inflammatory arthritis (IA)- and polymyalgia rheumatica (PMR)-like syndromes occur in about 6% of patients receiving an immune checkpoint inhibitor (ICI) and can worsen quality…Abstract Number: 0556 • ACR Convergence 2025
Evaluating the Efficacy of Sulfasalazine Compared to Placebo in the Treatment of Psoriatic Arthritis in Adults: A Systematic Review and Meta-Analysis
Background/Purpose: Available evidence hints towards the positive results of the use of sulfasalazine in the management of patients with psoriatic arthritis (PsA). We did a…Abstract Number: 0488 • ACR Convergence 2025
Early and Sustained Improvements in Disease Activity and Patient-Reported Outcomes in Patients Treated with Filgotinib for Rheumatoid Arthritis: Up to 2-Year Interim Real-World Data From FILOSOPHY and PARROTFISH
Background/Purpose: FILOSOPHY (NCT04871919) and PARROTFISH (NCT05323591) are ongoing, prospective, observational Phase 4 studies of filgotinib in patients (pts) with rheumatoid arthritis (RA) in Europe. In…Abstract Number: 0087 • ACR Convergence 2025
Integrative Metabolomic and Inflammatory Profiling in Rheumatoid Arthritis: Disease activity, therapeutic modulation, and underlying hepatic mechanisms
Background/Purpose: Lipid metabolism plays a key role in immune cell plasticity, influencing activation, differentiation and function. Inflammation alters this metabolism, contributing to disease progression. Extensive…Abstract Number: 2678 • ACR Convergence 2025
The Association Between Medication Taper Duration and Time to JIA Disease Flare: A Retrospective Cohort Study
Background/Purpose: Once clinically inactive, many patients with oligoarticular (oligoJIA) or polyarticular JIA (polyJIA) are interested in de-escalating therapy in a safe and successful manner. Many…Abstract Number: 2269 • ACR Convergence 2025
Key factors in optimizing the dose of Baricitinib in rheumatoid arthritis: a study based on routine clinical practice and its therapeutic implications
Background/Purpose: Baricitinib, a selective JAK1/JAK2 inhibitor, has demonstrated efficacy in rheumatoid arthritis (RA). In patients with stable disease control for at least six months, reducing…Abstract Number: 1587 • ACR Convergence 2025
Longitudinal Clinical Response to JAK Inhibitors in Systemic Sclerosis: A Real-Life Multicentric Study Across Clinical Domains
Background/Purpose: JAK inhibitors (JAKi) have shown promising early results in systemic sclerosis (SSc) patients, yet real-world data on their longitudinal effects across different disease domains…Abstract Number: 1336 • ACR Convergence 2025
Effectiveness of new initiators of tofacitinib and other biologic/targeted synthetic DMARDs in patients with rheumatoid arthritis
Background/Purpose: Though the efficacy and safety profile of tofacitinib in RA has been established in prior trials, the effectiveness of tofacitinib in routine care settings…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 48
- Next Page »